OptimizeRx Corporation (NASDAQ: OPRX) shares fell 26.7% to $16.32 after the company reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates.
PetIQ, Inc. (NASDAQ: PETQ) dipped 20.9% to $13.44 after the company posted downbeat Q2 sales and issued weak sales forecast.
Angi Inc. (NASDAQ: ANGI) dropped 16.7% to $5.11 after the company reported Q2 earnings results.
WeTrade Group, Inc. (NASDAQ: WETG) dipped 13.2% to $14.18. WeTrade Group entered into a strategic partnership with Jiqing, acquiring monkeypox test kits exclusive sales channel.
TTEC Holdings, Inc. (NASDAQ: TTEC) dropped 12.8% to $61.92 after the company issued Q3 and FY22 revenue guidance below estimates.
CAE Inc. (NYSE: CAE) fell 12.8% to $22.49 after the company reported worse-than-expected Q1 adjusted EPS results.
Certara, Inc. (NASDAQ: CERT) dipped 11.7% to $20.16 after the company reported worse-than-expected Q2 adjusted EPS and sales results and issued FY22 adjusted EPS and sales guidance below estimates.
Maxar Technologies Inc. (NYSE: MAXR) fell 8.4% to $26.17 after the company reported worse-than-expected Q2 sales results.
XP Inc. (NASDAQ: XP) dipped 7.8% to $21.82 following Q2 results.
Evotec SE (NASDAQ: EVO) fell 7.3% to $13.06 after Morgan Stanley downgraded the stock from Overweight to Underweight and announced a $16 price target.
Sanofi (NASDAQ: SNY) declined 6.4% to $45.51.
Nutex Health, Inc. (NASDAQ: NUTX) fell 6.4% to $3.68.
GoodRx Holdings, Inc. (NASDAQ: GDRX) declined 6.1% to $7.33. Morgan Stanley maintained GoodRx Holdings with an Equal-Weight and lowered the price target from $10.5 to $10.
Roblox Corporation (NASDAQ: RBLX) fell 5.8% to $44.56 after the company reported worse-than-expected Q2 EPS and sales results and announced bookings were 4% down year over year.
Alcon Inc. (NYSE: ALC) shares fell 4.6% to $71.89 after the company reported Q2 results.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
